18:03 , Sep 1, 2017 |  BC Week In Review  |  Company News

Gilead grabs Kite for nearly $12B

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...
16:28 , Aug 18, 2017 |  BC Week In Review  |  Clinical News

MAGEA3 T cell therapy safe, leads to responses in NCI study

In a study published in the...
20:51 , Aug 17, 2017 |  BC Extra  |  Clinical News

MAGEA3 T cell therapy safe, leads to responses in NCI study

In a study published in the...
21:41 , Jul 20, 2017 |  BC Innovations  |  Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR -like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the...
23:49 , Feb 28, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses A method for performing rapid structural analysis of fragmented protein crystals could help guide the development of drugs targeting difficult-to-crystallize proteins. The method involved breaking large imperfect or mosaic protein crystals into...
19:57 , Jan 13, 2017 |  BC Week In Review  |  Company News

Kite, Fosun deal

Kite and Fosun formed the JV Fosun Pharma Kite Biotechnology Co. Ltd. (Shanghai, China) to develop Kite's lead chimeric antigen receptor (CAR) T cell immunotherapy candidate, axicabtagene ciloleucel (KTE-C19), in China. The JV may also...
19:56 , Jan 13, 2017 |  BC Week In Review  |  Company News

Kite, Daiichi Sankyo deal

Kite granted Daiichi Sankyo rights in Japan to develop and commercialize chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (KTE-C19). Kite will receive $50 million up front and is eligible for up to $200...
20:34 , Nov 9, 2016 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Structural analyses of N. meningitidis PilE could help identify epitopes for use in developing vaccines to prevent the infection. An atomic model of PilE generated from 1.44 angstrom (Å)-resolution crystal structures and...
07:00 , Jul 14, 2016 |  BC Innovations  |  Tools & Techniques

Cryo-EM a river

Once considered the poor cousin in structural biology, cryo-electron microscopy (cryo-EM) has found new favor in industry, after technical improvements have broken barriers in molecular size and resolution, resulting in floods of data that can...
07:00 , May 26, 2014 |  BioCentury  |  Finance

Europe's Iceberg 2014: Premier League teams

Competing in biotech's Premier League requires deep pockets, long term planning and the risk appetite to pursue novel technologies or targets that don't always pan out. BioCentury's 12th annual European Iceberg survey reveals that for...